The National Pharmaceutical Pricing Authority (NPPA) has newly fixed or revised prices of 119 formulation packs and issued corrigendum orders on two insulin formulation packs for which it has revised prices in March, 2009.
The revised prices were announced on various forms, strengths and volumes of products including rifampicin with combinations, naproxen, vitamin A, ibuprofen with combinations, doxofylline, vitamin C with combinations, betamethasone with combinations, multivitamin and solu medrol/depo medrol/medrol (methyl prednisolone).
The maximum retail prices of monocomponent insulin Humalog and Huminsulin, imported by Eli Lilly and Company (India) Pvt Ltd, insulins Levemir, Novo rapid and Novo Mix of Novo Nordisk India Pvt Ltd, multivitamin Vitalux Plus TR of Novartis India Ltd, chloroxylenol product – Dettol – of Reckitt Benckiser (India Limited) and dextropropoxyphene combinations – Napsyvon and Cyclo Napsyvon of Wockhardt Ltd are also revised through notifications.
The corrigendum order on insulin clarifies that the earlier order fixing prices for insulin injection biphasic isophane as per the European Pharmacopoeia standards should be replaced with Indian Pharmacopoeia standards of insulin injection soluble and insulin injection isophane formulations.
“The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955,” says the notifications.